Investor Presentaiton

Non-GAAP Financial Measures Reconciliation Year Ended December 31, 2022 (unaudited) EBITDA Net Income (loss) Interest expense Accretion expense Income tax Depreciation and amortization EBITDA Stock-based compensation Impairment charges Provision for option liability Adjusted EBITDA EBITDA Net loss Interest expense Accretion expense Income tax Depreciation and amortization EBITDA Stock-based compensation Provision for option liability Adjusted EBITDA ($ 30,112) 1,739 681 202 4,060 (23,430) 1,418 3,540 (25) ($ 18,497) 2021 (unaudited) ($ 2,756) 1,081 556 (829) 1,114 (834) 1,913 9 $ 1,088 Three Months Ended June 30, 2023 2022 Six Months Ended June 30, 2023 (unaudited) (unaudited) (unaudited) 2022 (unaudited) ($5,262) 509 ($ 4,726) ($ 9,576) ($7,185) 439 1,018 846 171 (545) 171 341 341 (2,303) (171) (2,640) 181 (4,946) 66 260 365 518 (6,159) (8,023) (8,120) 249 56 572 (2) (25) ($ 4,880) ($ 5,912) ($ 7,967) ($7,573) Assure Neuromonitoring | 21

View entire presentation